{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056890","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.867496+00:00","generated_at":"2026-06-02T06:33:53.209849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Equillium Q1 revenue $10.7M, net loss $2.7M; positive lupus data, milestones ahead","bullets":["Revenue of $10.7M, up from $8.9M YoY, all from Ono partnership (development funding and amortization).","Net loss narrowed to $2.7M ($0.08 loss per share) vs $3.9M ($0.11) in Q1 2023.","Cash, cash equivalents and short-term investments $32.3M as of March 31, 2024; runway into 2H 2025.","Positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis announced in early April.","Upcoming: EQ101 Phase 2 alopecia areata topline data Q2 2024; EQUATOR interim review Q3 2024; Ono option exercise decision 2H 2024 (potential ~$32M payment)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056890","json":"https://secwatch.observer/filing/0000950170-24-056890.json","markdown":"https://secwatch.observer/filing/0000950170-24-056890.md","text":"https://secwatch.observer/filing/0000950170-24-056890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017024056890/0000950170-24-056890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017024056890/eq-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:33:53.209849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af029dca34b83e61d43c0295ad0ce907bb3af34d","claim":"Equillium, Inc. reported the first quarter ended March 31, 2024 results: revenue $10.7 million, net income $2.7 million, EPS $(0.08) per basic and diluted share.","evidence_excerpt":"1 Option exercise payment is denominated in Japanese yen (5 billion) and subject to currency exchange rates at the time of payment. Revenue for the first quarter of 2024 was $10.7 million, compared to $8.9 million during the same period in 2023. Revenue in the first quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000095017024056890/0000950170-24-056890-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$10.7 million"},{"label":"Net income","value":"$2.7 million"},{"label":"EPS","value":"$(0.08) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}